Results 201 to 210 of about 9,288 (216)

Ivacaftor/lumacaftor

Reactions Weekly, 2019
  +5 more sources

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine, 2014
Nicole Mayer-Hamblett, Scott Sagel, Bonnie Ramsey   +2 more
exaly  

Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor

Pediatric Pulmonology, 2019
Anthony J Fischer, Logan T Murry
exaly  

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

American Journal of Respiratory and Critical Care Medicine, 2015
Jeffrey Wagner, Michael Konstan, David Pasta   +2 more
exaly  

Ivacaftor

Reactions Weekly, 2015
openaire   +1 more source

Ivacaftor withdrawal

Reactions Weekly, 2022
openaire   +1 more source

Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data

Annals of the American Thoracic Society, 2019
Craig Winstanley, Freddy Frost, Dilip Nazareth   +2 more
exaly  

Clinical drug‐drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P‐glycoprotein

Journal of Clinical Pharmacology, 2015
exaly  

Elexacaftor/Ivacaftor/tezacaftor/Ivacaftor/tezacaftor

Reactions Weekly
openaire   +1 more source

Ivacaftor/lumacaftor

Reactions Weekly, 2018
openaire   +1 more source